Oct. 4, 2010
On October 5, 2010, Tasly Pharma, a Tianjin based pharmaceutical company, in-licensed the China rights to a clinical stage drug from ProteoTech, Inc., a private US drug-development company. The two companies will co-develop Exebryl-1, a small molecule for the treatment of mild-to-moderate Alzheimer's disease, working for approval on both the US and China regulatory paths. No details of terms were disclosed – but according to the consulting company that accompanied the deal, the agreement includes upfront payment, development costs and research funding. Tasly will hold the China rights, while rights for the rest of the world remain with ProeoTech.
To date, Exebryl-1 has been cleared for Phase I human clinical trials under FDA regulations.